$152.82 1.1%
GKOS Stock Price vs. AI Score
Data gathered: December 26

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Glaukos (GKOS)

Analysis generated September 30, 2024. Powered by Chat GPT.

Glaukos Corporation is a medical technology company focused on developing and commercializing novel ophthalmic products. The company's mission is to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) to deliver transformational outcomes for mild-to-moderate glaucoma patients. The company continues to advance a robust pipeline, including the expansion into new treatment modalities and further geographic markets.

Read full AI stock Analysis

Stock Alerts - Glaukos (GKOS)

company logo Glaukos | December 24
Insider Alert: Gilliam Joseph E is selling shares
company logo Glaukos | December 14
Insider Alert: Kliman Gilbert H is selling shares
company logo Glaukos | December 11
Price is up by 5.7% in the last 24h.
company logo Glaukos | December 6
Price is up by 5.1% in the last 24h.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.


Glaukos
Price $152.82
Target Price Sign up
Volume 31,700
Market Cap $8.34B
Year Range $96 - $152.82
Dividend Yield 0%
Analyst Rating 83% buy
Industry Medical Devices

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2497M87M74M-21M-18M-0.280
Q2 '2496M89M73M-51M-24M-0.520
Q1 '2481M88M65M-41M-31M-0.700
Q4 '2381M91M63M-37M-25M-0.630
Q3 '2375M73M60M-30M-21M-0.500

Insider Transactions View All

Gilliam Joseph E filed to sell 102,169 shares at $150.4.
December 23 '24
Gilliam Joseph E filed to sell 103,461 shares at $149.5.
December 23 '24
Kliman Gilbert H filed to sell 32,336 shares at $150.3.
December 23 '24
Kliman Gilbert H filed to sell 32,336 shares at $144.
December 13 '24
Kliman Gilbert H filed to sell 32,336 shares at $130.
September 11 '24

What is the Market Cap of Glaukos?

The Market Cap of Glaukos is $8.34B.

What is the current stock price of Glaukos?

Currently, the price of one share of Glaukos stock is $152.82.

How can I analyze the GKOS stock price chart for investment decisions?

The GKOS stock price chart above provides a comprehensive visual representation of Glaukos' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Glaukos shares. Our platform offers an up-to-date GKOS stock price chart, along with technical data analysis and alternative data insights.

Does GKOS offer dividends to its shareholders?

As of our latest update, Glaukos (GKOS) does not offer dividends to its shareholders. Investors interested in Glaukos should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Glaukos?

Some of the similar stocks of Glaukos are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.